Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
From March 7, 2020 to April 8, 2020, researchers observed the association between HCQ treatment and respiratory failure in confirmed COVID-19 patients at the New York–Presbyterian Hospital (NYP)–Columbia University Irving Medical Center (CUIMC). Patients were categorized as having been exposed to HCQ if administered the drug at any point after the study baseline (24 hours after being admitted to the emergency department) and before intubation/death. Researchers hypothesized that HCQ would be associated with a lower risk of a composite end point of intubation or death, after adjusting for and weighing confounding variables.
0
1
Tags
SARS-CoV-2 (COVID-19)
Biomedical Sciences
Related
A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19
Hydroxychloroquine as Prophylactic Treatment for COVID-19
Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19: Preliminary results from a multi-centre, randomized, controlled trial
Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State
Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis
Hydroxychloroquine for Early Treatment of Adults with Mild Covid-19: A Randomized-Controlled Trial
Learn After
Variables Assessed in Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Patient Outcomes in Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Limitations of Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19
Sample in Observational Study of Hydroxychloroquine in Hospitalized Patients with COVID-19